Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an 'off-the shelf' Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal Cancer

BASEL, Switzerland, Nov. 15, 2022 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced the first patient

Related Keywords

Ankara ,Turkey ,Switzerland ,Texas ,United States ,Eleanor Perkin ,Prnewswire Nouscom ,Rick Davis ,Marwang Fakih ,Sylvie Berrebi ,Bristol Myers Squibb ,Michaelj Overman ,Marina Udier ,Kostenloser Wertpapierhandel ,Linkedin ,University Of Texas Md Anderson Cancer Center ,Department Of Gastrointestinal Medical Oncology ,Janssen Research Development ,Microsatellite Instable High ,Principal Investigator ,Gastrointestinal Medical Oncology ,Cancer Center ,Science Translational ,Chief Executive Officer ,Lynch Syndrome ,Professor Marwan ,Based Vaccine Promotes Neoantigen Specific ,Science Translational Medicine ,Great Ape Adenoviral ,Modified Vaccinia Ankara ,Lynch Syndrome Carriers ,Myeloproliferative Neoplasms ,Janssen Research ,Nouscom ,Nnounces ,First ,Patient ,Hosed ,Hase ,Randomized ,Trial ,Yous ,Shelf ,Eoantigen ,Dancer ,Immunotherapy ,Mmr ,Thigh ,Metastatic ,Olorectal ,